BioCentury
ARTICLE | Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

Plus SAB gets additional funding from U.S. government, starts human trials

August 13, 2020 1:48 AM UTC


Access this Article